BOLT - Bolt Therapeutics up 7% on early-stage tumor candidate

2023-03-29 16:28:37 ET

• Bolt Therapeutics ( NASDAQ: BOLT ) is up 7% in after-hours trading after reporting positive top-line results on BDC-1001 both alone and in combination with Opdivo (nivolumab) for multiple tumor types.
• The Immune-Stimulating Antibody Conjugate is under investigation for HER2-expressing cancers.
• Results showed that target drug exposure levels were achieved at or near the recommended Phase 2 dose by more frequent administration such as every other week and weekly.
• Anti-tumor activity was seen with multiple partial responses, tumor shrinkage, and long-term stable disease across multiple HER2-expressing solid tumor types as monotherapy and with Opdivo.
• The company said that the data support the selection of a phase 2 dose and moving the candidate into phase 2.
• Bolt ( BOLT ) also said that it brokered an agreement with Roche ( OTCQX:RHHBY ) to to supply Perjeta (pertuzumab) to examine the biologic in combination with BDC-1001 for metastatic breast cancer.
• See why Seeking Alpha's Quant Rating views ( BOLT ) as a hold.

For further details see: